After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

Myosin modulators are a novel class of pharmaceutical agents that are being developed to
treat patients with a range of cardiomyopathies. The therapeutic goal of these drugs is to …

Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to
improve cardiac function in patients with heart failure with a reduced ejection fraction. Its …

Heart Failure Society (JHFS). The working committee for this project includes members and
collaborators involved in the previous versions of the heart failure guidelines and members …

Importance Heart failure with reduced ejection fraction is a progressive clinical syndrome,
and many patients' condition worsen over time despite treatment. Patients with more severe …

A central factor in the pathogenesis of heart failure (HF) with reduced ejection fraction is the
initial decrease in systolic function. Prior attempts at increasing cardiac contractility with oral …

Variants in> 12 genes encoding sarcomeric proteins can cause various cardiomyopathies.
The two most common are hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy …

Mitochondrial dysfunction characterized by impaired bioenergetics, oxidative stress and
aldehydic load is a hallmark of heart failure. Recently, different research groups have …

Acute heart failure (HF) and in particular, cardiogenic shock are associated with high
morbidity and mortality. A therapeutic dilemma is that the use of positive inotropic agents …

Abstract Background In GALACTIC-HF (Global Approach to Lowering Adverse Cardiac
outcomes Through Improving Contractility in Heart Failure)(n= 8,256), the cardiac myosin …